Febutaz 20mg Tablet

Febutaz 20mg Tablet is a tablet prescribed by the doctor that is mainly used to reduce high uric acid levels (hyperuricemia) to prevent gout attacks, joint damage, and related inflammation from crystal buildup.

Febutaz 20mg Tablet contains Febuxostat that non-competitively inhibit at the enzyme's active site, which lowers uric acid synthesis.​

• Reduce Hyperuricemia

Like any other chemical based medication, Febutaz 20mg Tablet   also has certain common side effects. Consult your doctor, if side effects persist for longer period of time.

• Pain in your muscles, bones, and joints Headache

• Headache
• Cough
• Diarrhea
• Nausea
• Weakness
• Itchy skin or rash
• Fever
• Pain in your muscles, bones, and joints
• Constipation
• Low Potassium
• Stomach Pain

• Severe Skin Reactions
• Pneumonitis
• Severe Allergic reaction
• Bone Marrow Supression
• Acute Kidney Injury
• Liver Infection

• The standard recommended starting dosage of Febutaz 20mg Tablet is once daily.
• This medicine is taken orally as whole with or without food but not on an empty stomach, without breaking, biting or chewing. Consult your doctor for exact dosage that is especially meant for you.​​
  

• Febutaz 20mg Tablet contains Febuxostat, a xanthine oxidase inhibitor. The enzyme xanthine oxidase, which breaks down purines by converting hypoxanthine to xanthine and subsequently to uric acid, is specifically blocked by febuxostat.
• Urate crystals in joints are dissolved and gout flare-ups are avoided because to this non-competitive inhibition at the enzyme's active site, which lowers uric acid synthesis.​
  

• Takata, T., Taniguchi, S., Mae, Y., Kageyama, K., Fujino, Y., Iyama, T., ... & Isomoto, H. (2025). Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia. Scientific Reports, 15(1), 8990. https://pubmed.ncbi.nlm.nih.gov/40089552/
• Lin, M., Zhang, H., Wu, H., Zhao, D., Nan, Z., & Fu, Y. (2025). Evaluation of febuxostat in treating diabetic kidney disease with hyperuricemia: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine, 12, 1657274. https://pmc.ncbi.nlm.nih.gov/articles/PMC12597919/
• Sarvepalli, R., & Penabaka, V. (2025). A Review on Febuxostat as Uric Acid Lowering Agent. Asian Journal of Medical and Pharmaceutical Sciences, 13(1), 17-20.
• Fan, X., & Wang, R. (2025). Drug-related gastric perforation secondary to prolonged febuxostat administration: a case report. Clinical Therapeutics. https://pubmed.ncbi.nlm.nih.gov/40222836/